Cargando…
Carbidopa suppresses prostate cancer via aryl hydrocarbon receptor-mediated ubiquitination and degradation of androgen receptor
Carbidopa, a peripheral decarboxylase inhibitor used with L-DOPA to treat Parkinson’s disease, has attracted significant interest in recent years for its anticancer effect. Increasing evidence reveals that Carbidopa can inhibit cancer cell growth and induce apoptosis through aryl hydrocarbon recepto...
Autores principales: | Chen, Zhiwei, Cai, Aimin, Zheng, Hailun, Huang, Huirong, Sun, Rui, Cui, Xiao, Ye, Weijian, Yao, Qing, Chen, Ruijie, Kou, Longfa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220950/ https://www.ncbi.nlm.nih.gov/pubmed/32404918 http://dx.doi.org/10.1038/s41389-020-0236-x |
Ejemplares similares
-
Carbidopa, an activator of aryl hydrocarbon receptor, suppresses IDO1 expression in pancreatic cancer and decreases tumor growth
por: Korac, Ksenija, et al.
Publicado: (2022) -
Simultaneous inhibition of aryl hydrocarbon receptor (AhR) and Src abolishes androgen receptor signaling
por: Ghotbaddini, Maryam, et al.
Publicado: (2017) -
The Impact of Indoles Activating the Aryl Hydrocarbon Receptor on Androgen Receptor Activity in the 22Rv1 Prostate Cancer Cell Line
por: Zgarbová, Eliška, et al.
Publicado: (2022) -
Constitutive Aryl Hydrocarbon Receptor Signaling in Prostate Cancer Progression
por: Ghotbaddini, Maryam, et al.
Publicado: (2018) -
Involvement of Aryl Hydrocarbon Receptor and Aryl Hydrocarbon Receptor Repressor in Helicobacter Pylori-related Gastric Pathogenesis
por: Zhu, Renfei, et al.
Publicado: (2018)